Hedy Teppler

Merck

Perfil externo:

Citaciones:

1458

Productos:

Productos

Patentes

Proyectos

Noticias

Coautorías según país de afiliación

Cargando información...

Evolución anual según la clasificación del ScienTI (Top 20)

Cargando información...

Fundadores:

Producto desarrollado por:

@colav
Contacto

ImpactU:

Acerca de ImpactU
Manual de usuario
Código Abierto
Datos Abiertos
Apidocs
Estadísticas de uso
Indicadores de Cooperación

Información:

ImpactU Versión 3.10.0
Última actualización:
Interfaz de Usuario: 26/06/2025
Base de Datos: 26/06/2025
Hecho en Colombia

Hedy Teppler

Merck

Perfil externo:

Citaciones:

1458

Productos:

Productos

Patentes

Proyectos

Noticias

Coautorías según país de afiliación

Cargando información...

Evolución anual según la clasificación del ScienTI (Top 20)

Cargando información...

12 Productos

Más citado

API

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Integrase inhibitor

Lamivudine

Medicine

Adverse effect

Pharmacology

Integrase

Reverse-transcriptase inhibitor

Viral load

Virology

Gastroenterology

Elvitegravir

Internal medicine

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virus

Chronic hepatitis

Publicado: 2007

Citaciones:

404

Altmétricas:

Artículo de revista

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic AnalysesAcceso AbiertoART-ART_A1

ID Minciencias: ART-0000671851-44

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Emtricitabine

Efavirenz

Medicine

Internal medicine

Confidence interval

Reverse-transcriptase inhibitor

Population

Viral load

Pharmacology

Gastroenterology

Virology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Environmental health

Publicado: 2010

Citaciones:

230

Altmétricas:

Artículo de revista

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected PatientsAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Emtricitabine

Medicine

Confidence interval

Internal medicine

Lamivudine

Liter

Viral load

Adverse effect

Human immunodeficiency virus (HIV)

Virology

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2013

Citaciones:

207

Altmétricas:

Artículo de revista

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsAcceso AbiertoART-ART_A1

ID Minciencias: ART-0000529818-193

Fuente: Clinical Infectious Diseases

Temas:

Raltegravir

Medicine

Antiretroviral therapy

Internal medicine

Integrase inhibitor

Pharmacotherapy

Drug

Human immunodeficiency virus (HIV)

Pharmacology

Viral load

Virology

Publicado: 2010

Citaciones:

204

Altmétricas:

Artículo de revista

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsAcceso AbiertoART-ART_A1

ID Minciencias: ART-0000529818-345

Fuente: The Lancet Infectious Diseases

Temas:

Raltegravir

Placebo

Medicine

Integrase inhibitor

Viral load

Clinical endpoint

Internal medicine

Adverse effect

Clinical trial

Gastroenterology

Pharmacology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virology

Pathology

Alternative medicine

Publicado: 2013

Citaciones:

126

Altmétricas:

Artículo de revista

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Lamivudine

Medicine

Reverse-transcriptase inhibitor

Liter

Integrase inhibitor

Adverse effect

Emtricitabine

Viral load

Gastroenterology

Internal medicine

Pharmacology

Virology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2009

Citaciones:

108

Altmétricas:

Artículo de revista

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialAcceso Abierto

Fuente: Clinical Infectious Diseases

Temas:

Emtricitabine

Efavirenz

Medicine

Lamivudine

Tolerability

Adverse effect

Internal medicine

Reverse-transcriptase inhibitor

Randomized controlled trial

Pharmacology

Viral load

Gastroenterology

Virology

Human immunodeficiency virus (HIV)

Virus

Antiretroviral therapy

Hepatitis B virus

Publicado: 2020

Citaciones:

Altmétricas:

Artículo de revista

Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind StudyAcceso Abierto

Fuente: Infectious Diseases in Obstetrics and Gynecology

Temas:

Ertapenem

Medicine

Piperacillin/tazobactam

Piperacillin

Tazobactam

Randomized controlled trial

Double blind

Multicenter study

Multicenter trial

Internal medicine

Meropenem

Antibiotics

Pseudomonas aeruginosa

Antibiotic resistance

Microbiology

Placebo

Genetics

Bacteria

Biology

Alternative medicine

Pathology

Publicado: 2002

Citaciones:

Altmétricas:

Artículo de revista

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRKAcceso AbiertoART-ART_A2

ID Minciencias: ART-0000671851-41

Fuente: HIV Clinical Trials

Temas:

Raltegravir

Efavirenz

Emtricitabine

Medicine

Tenofovir

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virology

Integrase inhibitor

Pharmacology

Viral load

Internal medicine

Publicado: 2012

Citaciones:

Altmétricas:

Artículo de revista

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Lamivudine

Tolerability

Integrase inhibitor

Medicine

Adverse effect

Pharmacology

Virology

Viral load

Reverse-transcriptase inhibitor

Internal medicine

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2012

Citaciones:

Altmétricas:

Artículo de revista

1
NaN
NaN / pág.

Cargando información...

12 Productos

Más citado

API

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Integrase inhibitor

Lamivudine

Medicine

Adverse effect

Pharmacology

Integrase

Reverse-transcriptase inhibitor

Viral load

Virology

Gastroenterology

Elvitegravir

Internal medicine

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virus

Chronic hepatitis

Publicado: 2007

Citaciones:

404

Altmétricas:

Artículo de revista

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic AnalysesAcceso AbiertoART-ART_A1

ID Minciencias: ART-0000671851-44

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Emtricitabine

Efavirenz

Medicine

Internal medicine

Confidence interval

Reverse-transcriptase inhibitor

Population

Viral load

Pharmacology

Gastroenterology

Virology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Environmental health

Publicado: 2010

Citaciones:

230

Altmétricas:

Artículo de revista

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected PatientsAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Emtricitabine

Medicine

Confidence interval

Internal medicine

Lamivudine

Liter

Viral load

Adverse effect

Human immunodeficiency virus (HIV)

Virology

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2013

Citaciones:

207

Altmétricas:

Artículo de revista

ID Minciencias: ART-0000529818-193

Fuente: Clinical Infectious Diseases

Temas:

Raltegravir

Medicine

Antiretroviral therapy

Internal medicine

Integrase inhibitor

Pharmacotherapy

Drug

Human immunodeficiency virus (HIV)

Pharmacology

Viral load

Virology

Publicado: 2010

Citaciones:

204

Altmétricas:

Artículo de revista

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsAcceso AbiertoART-ART_A1

ID Minciencias: ART-0000529818-345

Fuente: The Lancet Infectious Diseases

Temas:

Raltegravir

Placebo

Medicine

Integrase inhibitor

Viral load

Clinical endpoint

Internal medicine

Adverse effect

Clinical trial

Gastroenterology

Pharmacology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virology

Pathology

Alternative medicine

Publicado: 2013

Citaciones:

126

Altmétricas:

Artículo de revista

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Lamivudine

Medicine

Reverse-transcriptase inhibitor

Liter

Integrase inhibitor

Adverse effect

Emtricitabine

Viral load

Gastroenterology

Internal medicine

Pharmacology

Virology

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2009

Citaciones:

108

Altmétricas:

Artículo de revista

Fuente: Clinical Infectious Diseases

Temas:

Emtricitabine

Efavirenz

Medicine

Lamivudine

Tolerability

Adverse effect

Internal medicine

Reverse-transcriptase inhibitor

Randomized controlled trial

Pharmacology

Viral load

Gastroenterology

Virology

Human immunodeficiency virus (HIV)

Virus

Antiretroviral therapy

Hepatitis B virus

Publicado: 2020

Citaciones:

Altmétricas:

Artículo de revista

Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind StudyAcceso Abierto

Fuente: Infectious Diseases in Obstetrics and Gynecology

Temas:

Ertapenem

Medicine

Piperacillin/tazobactam

Piperacillin

Tazobactam

Randomized controlled trial

Double blind

Multicenter study

Multicenter trial

Internal medicine

Meropenem

Antibiotics

Pseudomonas aeruginosa

Antibiotic resistance

Microbiology

Placebo

Genetics

Bacteria

Biology

Alternative medicine

Pathology

Publicado: 2002

Citaciones:

Altmétricas:

Artículo de revista

ID Minciencias: ART-0000671851-41

Fuente: HIV Clinical Trials

Temas:

Raltegravir

Efavirenz

Emtricitabine

Medicine

Tenofovir

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Virology

Integrase inhibitor

Pharmacology

Viral load

Internal medicine

Publicado: 2012

Citaciones:

Altmétricas:

Artículo de revista

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 InfectionAcceso Abierto

Fuente: JAIDS Journal of Acquired Immune Deficiency Syndromes

Temas:

Raltegravir

Efavirenz

Lamivudine

Tolerability

Integrase inhibitor

Medicine

Adverse effect

Pharmacology

Virology

Viral load

Reverse-transcriptase inhibitor

Internal medicine

Human immunodeficiency virus (HIV)

Antiretroviral therapy

Chronic hepatitis

Virus

Publicado: 2012

Citaciones:

Altmétricas:

Artículo de revista

1
NaN
NaN / pág.